What’s the Difference? Umbilical Vs. Bone Marrow Stem Cells: Liveyon ‘Pure-Cast’ Sheds Light On The Issue

Reveals How New Technology Continues To Change Regenerative Medicine

 In an experimental industry filled with misconceptions and little public understanding, the Liveyon ‘Pure-Cast’recently answered an important question in the stem cell industry: What’s the difference between Umbilical and Bone Marrow Stem Cells.

Liveyon Founder and CEO John Kosolcharoen and Director of Education Dr. Alan Gaveck discussed the differences on ‘Pure-Cast’with stem cell experts, Dr. Margaret Coutts, Chief Scientific Officer for Liveyon and Dr. Rafael Gonzales, a prominent industry expert.

While bone marrow procedures were once known as a scientific breakthrough, Dr. Gaveck explains how new technology and discoveries have changed the field.

“There’s a lot of orthopedic surgeons out there still doing bone marrow procedures,” Dr. Gaveck said. “It was a great, great discovery many years ago, but now with some of the new technology, cord blood has hit the market.”

Dr. Gonzales broke down the differences of umbilical and bone marrow stem cells, noting age as an important factor.

“One is old and one is young,” Dr. Gonzales said. “That’s basically what it boils down to. It’s like a young baby skin versus an older individual’s skin. And even in culture, you can see this, the way it looks and the way it works. Individuals that are having these procedures done are getting bone marrow extracted. And they’re older already, and there’s something transpiring in the body that they need to have this done whether they’re 40 or 50.

Age is a vital factor because stem cell frequency decreases over time. During fetal development there are about 1 in 10,000 Mesenchymal Stem Cells (MCS), and around the age of 40, there are about 1 in 250,000 MCS—a significantly less frequency.

Dr. Coutts added that it’s the quality of stem cells also decreases.

“We all have stem cells and your skin looks different as you age,” Dr. Couttes said. “My hair gets replaced but now it’s gray. I still have hair stem cells but they’re not the same as they used to be. As you live your life, there’s environmental effects, pollutants, ultraviolet light from the sun. We accumulate DNA damage throughout our life. So cord blood is day zero.”

New technology has allowed umbilical cord treatment to change the industry. In fact, it paved the way for Liveyon to become the global leader in regenerative medicine—announcing this month the availability of Liveyon PURE® trial grade stem cell concentrate derived from umbilical cord blood.

Liveyon launched ‘Liveyon Pure Cast,’ to bring to light the truth about this emerging field and connecting doctors, researchers, patients, and the general public directly with well-respected industry leaders. The podcast provides a complimentary resource for clients of the company’s new product line.

Founded in 2016, Liveyon is pushing the boundaries of regenerative medicine with its innovative take on product research and development, manufacturing and distribution, and commitment to safety and transparency. Liveyon and Liveyon Labs Inc. are committed to achieving unparalleled stem cell potency through high live nucleated cell counts, while following validation protocols that produce an extremely consistent product for the most efficacious outcomes. The company’s dynamic ability to adapt to changing market trends and execute on opportunities has fortified its exponential growth and the company is poised to continue making a huge impact in the industry 2019.

To stay up-to-date on the regenerative medicine industry and receive notices of free upcoming live streaming video events, please subscribe to ‘Liveyon Pure-Cast.’

For more Liveyon Pure Cast Podcast videos subscribe to our YouTube channel at:

Want to learn more about Liveyon Stem Cells? Contact us for more information.

Translate »


Medical Professional Viewing Only (Disclaimer)

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.
The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.
“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.
If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.